$22.82
4.49% today
Nasdaq, Dec 04, 10:01 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US8036071004
Symbol
SRPT

Sarepta Therapeutics, Inc. Stock price

$21.84
-2.61 10.67% 1M
-17.03 43.81% 6M
-99.75 82.04% YTD
-104.17 82.67% 1Y
-101.12 82.24% 3Y
-131.49 85.76% 5Y
-14.44 39.80% 10Y
-0.48 2.15% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+1.37 6.69%

New AI Insights on Sarepta Therapeutics, Inc. Insights AI Insights on Sarepta Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$2.5b
Net debt
$184.2m
Cash
$851.0m
Shares outstanding
104.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.9 | 1.1
EV/Sales
1.0 | 1.2
EV/FCF
negative
P/B
1.7
Financial Health
Equity Ratio
38.6%
Return on Equity
15.4%
ROCE
-3.3%
ROIC
-4.9%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$2.4b | $2.1b
EBITDA
$-83.5m | $-320.7m
EBIT
$-86.0m | $-440.2m
Net Income
$-271.5m | $-460.7m
Free Cash Flow
$-388.8m
Growth (TTM | estimate)
Revenue
47.2% | 10.2%
EBITDA
-199.8% | -245.4%
EBIT
-206.1% | -301.8%
Net Income
-322.8% | -295.8%
Free Cash Flow
19.1%
Margin (TTM | estimate)
Gross
76.3%
EBITDA
-3.5% | -15.3%
EBIT
-3.6%
Net
-11.3% | -22.0%
Free Cash Flow
-16.1%
More
EPS
$-2.7
FCF per Share
$-3.7
Short interest
19.9%
Employees
1k
Rev per Employee
$1.4m
Show more

Is Sarepta Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Sarepta Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

13x Buy
37%
17x Hold
49%
5x Sell
14%

Analyst Opinions

35 Analysts have issued a Sarepta Therapeutics, Inc. forecast:

Buy
37%
Hold
49%
Sell
14%

Financial data from Sarepta Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,414 2,414
47% 47%
100%
- Direct Costs 573 573
148% 148%
24%
1,841 1,841
31% 31%
76%
- Selling and Administrative Expenses 527 527
0% 0%
22%
- Research and Development Expense 1,397 1,397
75% 75%
58%
-83 -83
200% 200%
-3%
- Depreciation and Amortization 2.55 2.55
1% 1%
0%
EBIT (Operating Income) EBIT -86 -86
206% 206%
-4%
Net Profit -272 -272
323% 323%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Sarepta Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sarepta Therapeutics, Inc. Stock News

Neutral
Business Wire
9 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved dosing in Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to evaluate the use of an enhanced immunosuppressive regimen as part of treatment with ELEVIDYS (delandist...
Neutral
Business Wire
10 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference (RNAi) ...
Neutral
Business Wire
10 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003 (formerly ARO-DM1), an investigational small interfering RNA (siRNA) therapeutic for the treatment of type 1 myotonic dystrophy (DM1). Cohorts 1 (1.5 mg/kg) and 2 (...
More Sarepta Therapeutics, Inc. News

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Head office United States
CEO Mr. Ingram
Employees 1,372
Founded 1980
Website www.sarepta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today